Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients With Small Cell Lung Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s216362
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-Small Cell Lung Cancer

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2017English

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

Oncologist
Cancer ResearchMedicineOncology
2019English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Prognostic Significance of CD31 Expression in Patients With Non-Small-Cell-Lung Cancer

Advances in Lung Cancer
2016English

Neural-Cadherin Expression Associated With Angiogenesis in Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2003English

Peripheral Immune Cell Gene Expression Predicts Survival of Patients With Non-Small Cell Lung Cancer

PLoS ONE
Multidisciplinary
2012English

Increased Expression of the Immunosuppressive Interleukin-35 in Patients With Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Clinicopathological and Prognostic Significance of Oct-4 Expression in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2016English

Prevalence of Epidermal Growth Factor Mutations in Patients With Non-Small Cell Lung Cancer in Turkish Population

Balkan Medical Journal
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy